Cipla Limited — Emtricitabine Exporter Profile
Indian Pharmaceutical Exporter · #5 for Emtricitabine · $2.0M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Emtricitabine with $2.0M in export value and 40 verified shipments. Cipla Limited holds a 1.8% market share in Emtricitabine exports across 10 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Emtricitabine Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Emtricitabine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $764.2K | 17 | 42.6% |
| UNITED STATES | $350.0K | 7 | 19.5% |
| COLOMBIA | $318.6K | 7 | 17.8% |
| CHILE | $150.0K | 3 | 8.4% |
| LIBYAN ARAB REPUBLIC | $50.0K | 1 | 2.8% |
| SINGAPORE | $50.0K | 1 | 2.8% |
| LIBYA | $50.0K | 1 | 2.8% |
| HONG KONG | $50.0K | 1 | 2.8% |
| MAURITIUS | $5.0K | 1 | 0.3% |
| JAMAICA | $4.9K | 1 | 0.3% |
Cipla Limited exports Emtricitabine to 10 countries. The largest destination is AUSTRALIA accounting for 42.6% of Cipla Limited's Emtricitabine shipments, followed by UNITED STATES (19.5%) and COLOMBIA (17.8%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Emtricitabine from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA AUSTRALIA PTY LTD | AUSTRALIA | $395.7K | 9 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $350.0K | 7 |
| APOTEX AUSTRALIA | AUSTRALIA | $200.0K | 4 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UP | COLOMBIA | $200.0K | 4 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $118.6K | 3 |
| CIPLA AUSTRALIA PTY LIMITED | AUSTRALIA | $118.5K | 3 |
| MEGALABS CHILE S,A, | CHILE | $100.0K | 2 |
| MEGALABS CHILE S A | CHILE | $50.0K | 1 |
| CIPLA AUSTRALIA PTY LTD, | AUSTRALIA | $50.0K | 1 |
| TO THE ORDER OF | LIBYAN ARAB REPUBLIC | $50.0K | 1 |
Cipla Limited supplies Emtricitabine to 15 buyers globally. The largest buyer is CIPLA AUSTRALIA PTY LTD (AUSTRALIA), followed by CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES) and APOTEX AUSTRALIA (AUSTRALIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Emtricitabine Export Value and How Much Does Cipla Limited Contribute?
India exported $51.2M worth of Emtricitabine through 2,194 shipments from 141 suppliers to 117 countries, serving 493 buyers globally. Cipla Limited contributes $2.0M to this total, accounting for 1.8% of India's Emtricitabine exports. Cipla Limited ships Emtricitabine to 10 countries through 15 buyers.
What Is the Average Shipment Value for Cipla Limited's Emtricitabine Exports?
Cipla Limited's average Emtricitabine shipment value is $50.0K per consignment, based on 40 shipments totaling $2.0M. The largest destination is AUSTRALIA (42.6% of Cipla Limited's Emtricitabine exports).
How Does Cipla Limited Compare to Other Indian Emtricitabine Exporters?
Cipla Limited ranks #5 among 141 Indian Emtricitabine exporters with a 1.8% market share. The top 3 exporters are MACLEODS PHARMACEUTICALS LTD ($14.0M), MYLAN LABORATORIES LIMITED ($13.3M), AUROBINDO PHARMA LTD ($5.9M). Cipla Limited processed 40 shipments to 10 destination countries.
What Emtricitabine Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| EMTRICITABINE AND TENOFOVIR DISOPROXIL F | $200.0K | 4 |
| TENOMUNE 300/200/600 TABLETS (EFAVIRENZ 600 MG,EMTRICITABINE 200MG AND TENOFOVIR DISOPROXIL FUMARATE 300 MG)( | $150.0K | 3 |
| CIPLA TENOFOVIR + EMTRICITABINE 200/300MG TABLET (INV.QTY.15529 PACK 1X30S=465870 NOS)NOS | $118.5K | 3 |
| CIPLA TENOFOVIR + EMTRICITABINE 200/300MG TABLET (1 X 30'S X 15,469 PACK =464070 NOS) | $95.7K | 3 |
| TENOMUNE 300/200/600 TABLETS (EFAVIRENZ600 MG, EMTRICITABINE 200 MG AND TENOFOVIR DISOPROXIL FUMARATE 300 MG) (INV.QTY | $75.8K | 2 |
| EMTRICITABINE CAPSULES 200MG NDC No 69097 642 02 ANDA No 091168 1 X 30S X 4584 PACK 137520 NUM | $50.0K | 1 |
| CIPLA TENOFOVIR EMTRICITABINE 200 300MG TABLET 15362PACKx1X30 S 460860NUM | $50.0K | 1 |
| CIPLA TENOFOVIR EMTRICITABINE 200 300MG TABLET INV QTY 15438 PACK 1X30S 463140 NOS | $50.0K | 1 |
| CIPLA TENOFOVIR EMTRICITABINE 200 300M | $50.0K | 1 |
| VIRTEN TABLETS TENOFOVIR 300MG EMTRICITABINE 200MG TABLETS 15456PACKSX1X30 S 463680 NOS | $50.0K | 1 |
Cipla Limited exports 30 distinct Emtricitabine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EMTRICITABINE AND TENOFOVIR DISOPROXIL F with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Emtricitabine to Key Markets
What Cipla Limited must comply with to export Emtricitabine to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Emtricitabine Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | AUROBINDO PHARMA LIMITED | $2.9M | 58 | 6 | $50.0K |
| 4 | LUPIN LIMITED | $2.1M | 43 | 4 | $50.0K |
| 5 | CIPLA LIMITED ★ | $2.0M | 40 | 10 | $50.0K |
| 10 | EMCURE PHARMACEUTICALS LIMITED | $1.5M | 52 | 20 | $28.5K |
| 9 | STRIDES PHARMA SCIENCE LIMITED | $650.0K | 13 | 6 | $50.0K |
Cipla Limited ranks #5 among 141 Indian Emtricitabine exporters. Average shipment value of $50.0K compared to the market average of $363.2K. The closest competitors by value are AUROBINDO PHARMA LIMITED and LUPIN LIMITED.
Which Indian Ports Ship Emtricitabine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 524 | 23.9% |
| SAHAR AIR | 469 | 21.4% |
| Bombay Air | 166 | 7.6% |
| DELHI AIR | 153 | 7.0% |
| DELHI AIR CARGO ACC (INDEL4) | 141 | 6.4% |
| NHAVA SHEVA SEA (INNSA1) | 60 | 2.7% |
| Bombay Air Cargo | 55 | 2.5% |
| HYDERABAD ACC (INHYD4) | 54 | 2.5% |
Geopolitical & Trade Policy Impact on Cipla Limited's Emtricitabine Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Emtricitabine, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Emtricitabine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Emtricitabine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 40 individual customs records matching Cipla Limited exporting Emtricitabine, covering 30 formulations to 10 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 117+ countries, 493+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Emtricitabine Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Emtricitabine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Emtricitabine Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Emtricitabine. For current shipment-level data, contact TransData Nexus.